Soligenix (SNGX) announced a publication describing the preclinical efficacy of CiVax, a thermostabilized subunit vaccine against SARS-CoV-2. Using custom-developed immunoassays, the combination of a primary adenovirus vaccine – COVID-19 Vaccine AstraZeneca – coupled with a CiVax booster was shown to induce broader protection against COVID-19 variants in non-human primates than a 2-shot mRNA series in humans. CiVax is the company’s heat stable subunit vaccine candidate for the prevention of COVID-19, the infection caused by SARS-CoV-2. “Our ThermoVax platform has successfully thermostabilized vaccines for ricin toxin, for filoviruses such as Ebola, Sudan and Marburg, and for COVID, and as such is a well-established thermostabilization strategy that enhances the standard protein subunit vaccination technology. We believe this enhancement makes protein subunit vaccines, the gold standard for safe vaccines, competitive with other vaccine technologies, such as mRNA, which have much more stringent cold-storage requirements,” stated CEO Christopher Schaber. “The ability of CiVax to induce rapid broad immune coverage, including against SARS-CoV-2 variants, even when administered after other primary vaccination series, is another marked advantage…This platform may also aid in the preparation for future pandemics.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX: